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Abstract 
Objective: To determine the effect of SGLT2 inhibitor dapagliflozin on glucose 
flux, lipolysis and ketone body concentrations during insulin withdrawal in 
people with type 1 diabetes.  
 
Research Design and Methods: A double-blind placebo controlled crossover 
study with a 4-week wash out period was performed in 12 people with type 1 
diabetes using insulin pump therapy.  Participants received dapagliflozin or 
placebo in random order for 7 days. Stable isotopes were infused to measure 
the rate of glucose production (Ra), disappearance (Rd) and lipolysis. At 
isotopic steady state insulin was withdrawn and the study terminated after 600 
minutes or earlier if blood glucose reached 18mmol/L, bicarbonate <15mmol/L, 
venous pH <7.35 or capillary ketones >5.0 mmol/L.  
Results: At baseline, glucose Ra was significantly higher with dapagliflozin 
than placebo. Following insulin withdrawal, plasma glucose concentrations at 
the end point were significantly lower with dapagliflozin than placebo and 
AUC0-180min glucose Rd and AUC0-180min β-hydroxybutyrate (BOHB) were 
significantly higher. There was a small but significantly higher AUC0-180min 
glycerol Ra (measure of lipolysis) with dapagliflozin. Non-esterified fatty acid 
concentrations were not different between treatments. 
When divided by BMI>27 and <27kg/m2, basal glucose Ra and BOHB, and 
AUC0-180min glycerol Ra were significantly higher in the low BMI group with 
dapaglifozin versus placebo treatment. 
Conclusions: During insulin withdrawal the increase in BOHB with 
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dapaglifozin may be partially due to increased lipolysis. However reduced 
renal excretion, reduced BOHB uptake by peripheral tissues or a metabolic 
switch to increase ketogenesis within the liver may also play a role.  
 
SGLT2 inhibitors are selective and reversible inhibitors of renal SGLT2, the major 
transporter responsible for renal glucose reabsorption. They lower plasma glucose 
by reducing renal glucose reabsorption and enhancing urinary glucose excretion. In 
type 2 diabetes, this results in a compensatory increase in endogenous glucose 
production, lower tissue glucose uptake and higher glucagon levels (1). 
  
It has been postulated that the SGLT2 inhibitor class may have beneficial effects in 
the management of type1 diabetes. Phase 2 and 3 clinical trial studies have shown 
encouraging results with lower HbA1c levels, reduced weight and insulin 
requirements (2-7). However, significant safety issues have been highlighted in 
clinical trials with increased rates of ketoacidosis, although rates differed between 
trials. In DEPICT-1 diabetic ketoacidosis (DKA) occurred in 1% and 2% of the 5mg 
and 10mg dapagliflozin groups respectively (2). Pooled data from the 26-week 
EASE-2 and EASE-3 studies showed DKA occurred in 0.8%, 3.3% and 4.3% of the 
empagliflozin 2.5mg, 10mg and 25mg arm respectively and 1.2% in the placebo arm 
(4). In Tandem-1 euglycemic ketoacidosis occurred in 3.4% and 4.2% of the 200mg 
and 400mg sotagliflozin groups and 0.4% in the placebo group over 24 weeks (6). 
Finally, in an 18-week randomised study with canagliflozin, ketone related adverse 
events occurred in 5.1% of the 100mg arm and 9.5% of the 300mg arm (7). 
 
The FDA have not approved SGLT2 inhibitors for use as an adjunct therapy in type 1 
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diabetes and have warned about the risk of euglycemic DKA. A number of triggers 
for ketoacidosis were identified. These included reduced calorie intake, lower insulin 
doses and illness. It is also important to note that very few participants experienced a 
state of illness or inter-current stress during the reported clinical trials. A recent study 
estimated real world experience rates of DKA with off-label use of SGLT2 inhibitors 
in patients with type 1 diabetes to be higher than expected based on the sotagliflozin 
clinical trials (8). However, in March 2019, dapagliflozin was approved in Europe for 
people with type 1 diabetes as an adjunct to insulin in people with a body mass index 
greater than 27kg/m2. (9) and received evidence-based recommendation by National 
Institute for Clinical Excellence (NICE) in August 2019 (10). 
The incidence of DKA is between 0 – 56 cases per 1000 person – years amongst 
people with type1 diabetes (11); the pathogenesis of DKA is well known. In the 
absence of adequate direct insulin action in the liver the excess glucose production 
is so great that an increase in glucose dependent peripheral glucose uptake and 
associated glycosuria fail to limit progressive hyperglycaemia. Lipolysis is increased 
due to lack of insulin’s action on hormone sensitive lipase resulting in increased 
release of non-esterified fatty acids (NEFA) and glycerol from adipose triglyceride 
stores (12). In the liver, due to the diversion of oxaloacetate towards 
gluconeogenesis, there is a reduced capacity of the Krebs cycle to oxidise acetyl 
CoA derived from the β oxidation of NEFA. Consequently, there is an increased flux 
of acetyl CoA towards ketogenesis giving rise to increased acetoacetate, BOHB and 
acetone (13). Hence, in insulin deficiency, there are two parallel metabolic 
processes: glucose over-production and ketone over-production. 
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The potentially life-threatening state of euglycemic DKA is unusual and was first 
described in 1973 (14). A speculative mechanism for its development with SGLT2 
inhibitors is that the insulin independent removal of glucose from the body enables 
glycemic control concurrent with either an absolute or relative deficiency of insulin. In 
addition, ketoacidosis may be driven by an increase in counter regulatory hormones 
i.e. glucagon, cortisol or growth hormone. Using stable isotope techniques, this study 
explored these potential mechanisms by studying the effect of SGLT2 inhibitor, 
dapagliflozin on glucose flux, lipolysis and ketone body concentration during 
hyperglycaemia in people with absolute endogenous insulin deficiency.  
 
RESEARCH DESIGN AND METHODS 
A single centre investigator led, double-blind placebo controlled cross over study 
with a 4-week wash out period was performed in patients with type 1 diabetes using 
insulin pump therapy.  Ethics approval was granted from HRES committee: Southern 
Central Berkshire B. The clinical trial was registered with the European Clinical Trials 
Database (EudraCT) under the number 2015-002094-38. The study was funded by 
Diabetes UK and Investigational Medicine Product (IMP) provided by Astra Zeneca 
Ltd.  
Participants with type 1 diabetes for greater than 12-months were recruited between 
February 2018 – October 2018 using the diabetes insulin pump database at the 
Royal Surrey County NHS Hospital. Type 1 diabetes was established by clinical 
presentation, treatment response and C-peptide level. Exclusion criteria included 
proliferative retinopathy requiring acute treatment within last three months, moderate 
to severe renal impairment (creatinine clearance [CrCl] < 60 mL/min or estimated 
glomerular filtration rate [eGFR] <60 mL/min/1.73 m2, severe hepatic impairment, 
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NYHA class III-IV cardiac failure, uncontrolled cardiac arrhythmia, uncontrolled 
hypertension, mental incapacity, pregnancy or breast feeding, those of child-bearing 
potential not taking adequate contraception precautions and suspected allergy to trial 
products.   
Design 
Participants received dapagliflozin (10 mg daily) or placebo in random order for 7 
days. They were made aware of potential changes in glycemic control and were 
asked to record trial medication administration, any concomitant medication (to 
include insulin), hypoglycaemia frequency (capillary glucose level <4mmol/L), fasting 
ketone levels and any adverse events.  
On day 7, participants attended for a metabolic study. They were asked not to 
consume food and to drink only water from 22:00 hours the day before. They were 
also asked not to undertake any strenuous exercise or consume alcohol for 24h 
before the study day. All participants were using continuous subcutaneous insulin 
therapy and disconnected their insulin pumps at 06:00 hours on the morning of a 
metabolic study. They were transferred to a soluble variable insulin infusion to 
maintain a whole blood concentration glucose at 5 mmol/L. [6,6-2H2]glucose and 
[1,1,2,3,3 5H2]glycerol were infused from -120 min to the study endpoint to measure 
glucose Ra and Rd and lipolysis respectively (Cambridge isotopes, CK Gas Products 
Ltd, Ibstock, UK).  
At 0 min, when isotopic steady state had been achieved, insulin was withdrawn, 
participants were given a single dose of study medication and blood glucose allowed 
to increase.  
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Blood samples were taken to measure plasma glucose and glycerol enrichment and 
concentration, and concentrations of non-esterified fatty acid (NEFA) and plasma 
BOHB every 20 minutes until 180 minutes and then at 30 minute intervals. Interval 
urine collection was also taken and blood samples for counter regulatory hormones 
were taken to measure plasma glucagon, and serum insulin, growth hormone and 
cortisol concentrations at 120 minute intervals. Urine samples were collected over 2 
hour intervals for measurement of glucose and spot urinary ketones.  
Rescue and study termination 
At 600 minutes (10 hours) or in the event of blood glucose of 18mmol/L, bicarbonate 
<15mmol/L or venous pH <7.35 or point of care capillary ketone level of >5.0 mmol/L 
the metabolic study was terminated and participants commenced on rescue 
intravenous insulin infusion and 5% dextrose until blood glucose levels stabilised. 
Plasma measurements 
On the study day plasma glucose concentration was measured using a glucose 
oxidase technique on a glucose analyser (YSI 2300 Clandon Scientic, Yellow 
Springs Instruments, Yellow Springs, OH, USA). Whole-blood samples were 
immediately centrifuged, and aliquots of plasma stored at -80oC to be analysed at a 
later date in a laboratory setting.  
Plasma glucose concentrations were measured with a Roche Cobas MIRA analyser 
using the ABX Pentra glucose kit (Horiba ABX, Northampton, UK) and plasma 
glycerol and BOHB concentrations using Randox kits (Glycerol and RANBUT; 
Randox Laboratories, Co. Antrim, UK). Plasma NEFA concentrations were 
measured using an enzymatic kit from (WAKO Chemicals GmbH, Neuss Germany). 
8 
 
Insulin and glucagon were measured using radioimmunoassays purchased from 
Merck Millipore, Merck Chemicals, Nottingham, UK). Serum cortisol concentration 
were measured using an in-house radioimmunoassay.  Serum Growth hormone 
concentrations were measured using an immunoradiometric kit purchased from DRG 
Instruments GmbH, supplied by IDS, Tyne and Wear, UK. The isotopic enrichment of 
plasma glucose was determined as the trimethylsilyl-O-methyloxime derivative (15) 
using gas chromatography-mass spectrometry (model 5975 CMSD inert XL EI/CI 
MSD; Agilent Technologies, Wokingham, UK). The isotopic enrichment of plasma 
glycerol was determined as the tert-butyl trimethylsilyl glycerol derivative (16) using a 
gas chromatography-mass spectrometry model 5975 network MSD (Agilent 
Technologies).  
Glucose rate of appearance (Ra), rate of disappearance (Rd) and glycerol 
production were calculated using Steele’s non-steady state equations modified for 
stable isotopes (17).  
Statistical analysis 
Statistical analysis was performed using R version 3.5.1 and SAS version 9.4 or 
above. All hypothesis tests were two sided and evaluated at a significance level of 
5%. 
The primary end point was glucose concentration, as measured at 600 minutes or at 
the time of glycemic rescue, whichever occurred first. The study was powered for 12 
subjects. In a recent study where insulin was withdrawn in people with type 1 
diabetes the SD for plasma glucose concentration was 20% (18). With 12 subjects, 
each studied with and without the SGLT2 inhibitor and a SD of 20% a difference in 
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plasma glucose of 24% can be detected with 80% power and two-sided significance 
level of 5%.  
 
Final glucose concentration was statistically analysed as the response variable in a 
general linear mixed model (using PROC MIXED procedure in SAS software), with 
treatment, period, treatment by period interaction, as fixed effects, and the baseline 
glucose concentration as a covariate. The participant was a random effect in the 
model. The denominator degrees of freedom were adjusted using the Kenward-
Roger approximations. 
 
The secondary endpoints were statistically evaluated as response variables using a 
general linear mixed model with treatment, period, time, treatment by period and 
treatment by time interactions as fixed effects, baseline measurement as a covariate, 
participant as a random effect, time as a repeated measure with SP(POW) variance-
covariance structure. Denominator degrees of freedom were adjusted using the 
Kenward-Roger approximations. All other response variables measured or derived 
once per participant in each period, were analysed as per the primary endpoint. 
 
In order to assess the impact of participant BMI level on study conclusions the 
participants were classified as ‘high BMI’ (BMI > 27kg/m2, N = 5) or ‘low BMI’ (BMI < 
27kg/m2, N = 7). The data for which a single value per participant per period was 
analysed were then re-analysed as above with the modification that the model 
independent variables included, additionally, the BMI classification and the 
interaction of the BMI classification with treatment. The estimate of- and p-value for- 
the treatment effect at each separate level of BMI the same information for the effect 
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of BMI at each separate treatment were reported in addition to the results reported 
above. 
 
The data for which several time point values per participant per period were 
analysed were then re-analysed as above with the modification that the model 
independent variables included, additionally, the BMI classification, the interaction of 
the BMI classification with treatment and the interaction of the BMI classification and 
treatment and time point. For each separate time point the same additional estimates 
of effect and p-value for BMI and treatment combined, as immediately above, were 
reported. 
 
Area under the curves were calculated for study points 0-180 min with and without 
correction for the baseline. In the figures the mean values at each time point only 
include data where there is a measurement from both arms of the study at that time 
point. We have called these paired measurements. 
 
Results 
Twelve people (4 male & 8 female) with type 1 diabetes, duration of diabetes 
23.3±4.1 y (age 40.7±3.9 years, BMI 26.8±1.4, HbA1C 59.9±2.3 mmol/mol) 
completed the study. All participants had C-peptide <0.2 nmol/L apart from  one 
participant who had a C-peptide level of 0.314 nmol/L and 0.352 nmol/L in the 
dapagliflozin v placebo arm respectively with duration of type 1 diabetes of 17y). 
 
During the seven day treatment period there was no significant difference in insulin 
dose between dapagliflozin v placebo (0.056±0.007 U/kg vs 0.058±0.008 U/kg, 
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respectively). Two participants reduced their basal setting due to hypoglycaemia. 
Other participants did not change their insulin dose but encountered more hypos 
overnight which were remedied by taking Gluco gel (hypoStop gel).  
The duration of each metabolic study prior to termination or rescue varied from 180 
to 600 min. All subjects completed 180 minutes of each metabolic study.  The 
average time for each metabolic study was not different between dapagliflozin (418 ± 
44 min) and placebo (448 ± 38 min).  
 
Glucose Concentration (Figure 1) 
At 0 min, glucose concentration was not different between treatments. Following 
insulin withdrawal, plasma glucose concentration increased in both groups but at the 
end of the study (600 min or time of rescue) the mean glucose concentration was 8.5 
± 0.7mmol/L with dapagliflozin treatment and 14.3 ± 1.1 mmol/L with placebo 
(p=0.0005) (Figure 1). Urinary glucose excretion between 0-120 min (n=6) was 5.10 
± 0.80 micromol/kg/min with dapagliflozin and 0.029 ± 0.01 micromol/kg/min with 
placebo (p=0.003).  
Glucose Metabolism (Figure 1 and Table 1) 
At baseline (0 min), when isotopic enrichment and glucose concentration were in a 
steady state glucose Ra was significantly higher with dapagliflozin compared with 
placebo (p=0.0088). At this time point glucose Rd is equal to glucose Ra. During 
insulin withdrawal glucose Ra increased, peaking at 90 minutes and then declined 
with no difference in AUC between treatments. AUC0-180 min Glucose Rd and MCR 
were higher with dapagliflozin compared with placebo (p=0.0041, p<0.0001). 
BOHB, Non-esterified Fatty Acid and Glycerol Metabolism (Figure 2 and Table 
1) 
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Baseline. There was no difference in baseline glycerol Ra (a measure of lipolysis) 
between treatments. Baseline BOHB was higher with dapagliflozin (0.39±0.11 vs 
0.16±0.05 mmol/L, p=0.044) and NEFA concentration was higher (0.61±0.09 vs 
0.47±0.07 mmol/L) although this was borderline significant (p=0.054). There was a 
significant positive relationship between NEFA and BOHB with both treatments 
(Supplement figure 3). Base excess concentration and venous bicarbonate were 
lower with dapagliflozin versus placebo (0.61±0.0.6 vs 1.66 ± 0.48mmol/L, p=0.0095 
and 24.1±0.4 vs 24.9±0.30mmol/L, p=0.028 respectively). 
During insulin withdrawal. AUC0-180 min BOHB was higher with dapagliflozin compared 
with placebo (149±26 vs 117±18 mmol/L*min, p=0.035). NEFA, venous bicarbonate, 
pH and capillary ketones and urinary ketones were not statistically different but there 
was a small but significantly higher AUC0-180 min glycerol Ra.  
AUC0-180 min BOHB and AUC0-180 min glycerol Ra were negatively correlated with BMI 
with both dapagliflozin (r=-0.58, p=0.048 and r=-0.625, p=0.030 respectively) and 
placebo (r=-0.77, p=0.003 and r=-0.757, p=0.004) (Supplemental Figure 1) 
Counter Regulatory Hormones 
At arrival (-120 min), glucagon was significantly higher with dapagliflozin treatment 
compared to placebo (42.1±3.8 vs 35.2±3.9 ng/L, p=0.0127). Insulin at arrival was 
not different between dapagliflozin and placebo (231±40 vs 264 ± 50 pmol/L).  
Glucagon/insulin ratio at arrival was also not significantly different between 
dapagliflozin and placebo (0.24±0.04 vs 0.19±0.02 ng/pmol).  
At 0 min neither insulin (214 ± 45 vs 235 ± 46 pmol/L) nor glucagon (35.8 ± 2.5 vs 
31.2 ± 3.8 ng/L) were different between dapagliflozin and placebo respectively but 
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the glucagon/insulin ratio was higher with dapagliflozin (0.27 ± 0.06) than placebo 
(0.16 ± 0.02 ng/pmol, p= 0.04).  
During insulin withdrawal neither insulin, glucagon nor the glucagon/insulin ratio 
were significantly different in the two treatment arms (Supplement Figure 2) 
There was no statistical difference in growth hormone concentration or cortisol 
concentration at any time point. 
Subgroup analysis  
In people with BMI< 27 kg/m2 vs BMI>27kg/m2, there was no significant difference in 
HbA1c (61±1.2 vs 59±1.6 mmol/mol) or duration of diabetes (18.7±5.4 y vs 29.8±5.6 
y, respectively) (Supplement Table 2) 
 
Baseline glucose Ra, baseline BOHB and AUC0-180 min glycerol Ra were higher in the 
low BMI group with dapaglifozin versus placebo treatment (p=0.001, p=0.019 and 
p=0.012 respectively). These measurements were not different in the high BMI group 
with dapaglifozin versus placebo treatment (Table 2).  NEFA concentrations were not 
different between dapagliflozin versus placebo in either group (Supplement Table 2). 
 
When treated with placebo baseline insulin concentration was significantly higher in 
the high BMI vs low BMI group (p=0.046) (Table 2).  
With both dapagliflozin and placebo, NEFA concentration at baseline (both p<0.05, 
Supplement Table 2) and AUC0-180 min BOHB (p<0.01, p<0.05, Table 2) were 
significantly lower in the high BMI vs low BMI group (Supplement Table 2).  
Discussion 
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This study provides clear evidence that when dapagliflozin was used as an adjunct 
therapy in people with type 1 diabetes using insulin pump therapy, plasma BOHB 
was higher versus placebo both in the presence of insulin treatment and during 
insulin withdrawal. The power of this study from the clinical perspective was the 
crossover design with each individual undergoing an identical insulin withdrawal 
protocol with the only difference being the presence or absence of a SGLT2 inhibitor.   
The primary endpoint was plasma glucose concentration at the end of study. This 
was significantly lower during dapagliflozin treatment than placebo, while the time to 
study termination did not differ between the two treatments. It is therefore reassuring 
from a clinical perspective that there was no difference in the time to rescue with 
either dapagliflozin or placebo. However, it highlights that glucose levels in the 
presence of dapagliflozin may not be used as a marker for insulin deficiency in 
patients during patient guided ‘sick day rules’.   
 
It has been hypothesised that SGLT2 inhibition with single dosing empagliflozin in 
people with type 2 diabetes results in a reduction in insulin secretion and an 
augmented glucagon response, which in turn enhances gluconeogenesis and 
lipolysis (1). The higher baseline glucose Ra with dapagliflozin, in the current study, 
may be due to augmented gluconeogenesis caused by the increased 
glucagon/insulin. Another possibility, is that it maybe due to the increase in glucose 
Rd, although the study cannot determine whether the increase in glucose Rd is due 
to increased glucose excretion only or also due to an increase of tissue glucose 
uptake stimulated by dapagliflozin.  
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Although at baseline there was no difference in glycerol Ra (a measure of lipolysis), 
NEFA concentration was higher with dapagliflozin. The strong relationship between 
NEFA and BOHB at baseline and during insulin withdrawal suggests NEFA flux to 
the liver was driving the higher BOHB with dapagliflozin.  When we divided the 
subjects based on BMI, this effect was only seen in those with a low BMI i.e. the 
BOHB response to dapagliflozin at baseline and the rise in glycerol Ra during insulin 
withdrawal was higher than placebo. This was not seen in the high BMI group. There 
was a striking negative relationship between lipolysis and BMI and ketone levels and 
BMI. While this is only a small group and we must highlight that the study design was 
not powered to look at the difference between BMI, it suggests a greater risk of 
ketosis in people with type 1 diabetes with a low BMI which maybe of clinical 
relevance. Although baseline NEFA concentration was higher with dapagliflozin 
there was no difference in NEFA concentration with dapagliflozin in both the whole 
group and the BMI subgroups following insulin withdrawal. However, it’s possible 
that an increase in NEFA production was matched by an increase in NEFA 
clearance.  
 
Individuals with a BMI>27kg/m2 also required greater insulin doses and had higher 
plasma insulin concentrations than people with a BMI <27 kg/m2 leading to lower 
plasma level of ketones. This can be clinically important, because it suggests that 
the greater insulin requirement in people with a BMI >27kg/m2, is likely to minimize 
the risk of ketoacidosis caused by SGLT2 therapy. 
 
While an increase in ketogenesis driven by lipolysis is one mechanism for the rise in 
BOHB, the rise in lipolysis with dapagliflozin was small and we cannot rule out the 
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possibility that reduced ketone uptake by peripheral tissues or reduced urinary 
excretion of ketones may also play a role. The excretion of ketones occurs by a 
balance between glomerular filtration and tubular reabsorption. Experimental and 
clinical data have established that SGLT2 inhibition can reduce glomerular filtration 
rate in people with type 1 and 2 diabetes thereby reducing renal ketone excretion 
(21). In the current study, although plasma ketone concentrations were higher during 
dapagliflozin treatment urinary ketone concentrations were not different from 
placebo. This contrasts with a study in people with type 2 diabetes which showed 
increased clearance and fractional urinary excretion of β-hydroxybutyrate after single 
and 4 week chronic use of empagliflozin (19..   
 
In the presence of prolonged insulin withdrawal secondary to periods of illness or 
stress there may also be upregulation of the renal reabsorption capacity of ketones 
but this needs further investigation. This also has clinical implications as historically, 
ketonuria has been used to screen for the presence of ketosis (20.). 
 
It has been suggested that short term fasting and dehydration predisposes people 
with type 1 diabetes to develop euglycemic DKA during periods of insulin withdrawal 
/ deficiency (21). SGLT2 inhibitors may by nature of their mechanism of action further 
predispose a person to the risks of euglycemic DKA. SGLT2 inhibitors lower the 
glucose availability during insulin deficiency by encouraging glucose excretion and 
fluid loss through persistent glycosuria. The base excess concentration at baseline 
(mmol/L) was statistically higher for the dapagliflozin group indicating a greater need 
to balance acid to ensure a normal body pH with administration of SGLT2 inhibitors. 
The SGLT2 inhibitor was only taken for a short term and further evidence is required 
to establish any longer-term adaptions if administered on a regular basis.  
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In summary, this study provides evidence that when used as an adjunct therapy in 
people with type 1 diabetes using insulin pump therapy, there is a rise in ketones 
during insulin deficiency. This has clinical implications. The stability of glucose levels 
indicates that there will need to be more reliance on capillary ketone monitoring with 
SGLT2 inhibitors to prevent this predictable and preventable risk (22). Emphasis 
should be in ensuring adequate basal insulin levels and avoiding calorie restriction 
and dehydration. The patient and clinician will need to be constantly vigilant and 
there must be a low threshold for stopping this class of drug during periods of illness 
or inter-current stress (23). A four-step approach to address the risk of DKA during 
treatment with SGLT2 inhibitors in people with type 1 diabetes has been suggested 
as a life saving measure to help clinicians and patients (24). In addition, an 
international consensus has been published to address the risk management of DKA 
in people with type 1 diabetes (25). SGLT2 inhibitors are now being used in clinical 
practice both within and outside of licence and we watch with interest the clinical 
benefits and risks of this class of drug as we gain more real-world experience in 
people with type 1 diabetes.  
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Table 1. Baseline, AUC and incremental AUC from 0-180 min for glucose, glycerol 
and BOHB metabolism at the end of 7days treatment with dapagliflozin or placebo. 
Results are mean ± SEM. 
 Dapagliflozin Placebo P Value 
Baseline C-peptide concentration 
(nmol/L) 
0.10±0.02 0.10±0.03 0.470 
Glucose concentration at baseline 
(mmol/L) 
5.43±0.14 5.74±0.17 0.180 
AUC0-180 glucose concentration 
(mmol/L*min) 
1450±70 1744±87 0.015 
Incremental AUC0-180 glucose 
concentration (mmol/L*min) 
464±77 720±81 0.026 
Glucose Ra at Baseline 
(micromol/min/kg) 
13.0±0.77 11.7±0.7 0.009 
Glucose Ra AUC0-180 (micromol/kg) 3337±271 2969±216 0.157 
Glucose Ra incremental AUC0-180 
(micromol/kg) 
879±180 758±127 0.596 
Glucose Rd at Baseline 
(micromol/min/kg) 
13.1±0.7 11.8±0.6 0.009 
Glucose Rd AUC0-180 (micromol/kg) 2728±222 2014±147 0.004 
Glucose Rd incremental AUC0-180 
(micromol/kg) 
593±140 275±100 0.049 
Glucose MCR at Baseline 
(ml/min/kg) 
2.43±0.14 2.06±0.06 0.008 
Glucose MCR AUC0-180 (ml/kg) 347±26 215±9 <0.001 
Glucose MCR incremental AUC0-180 
(ml/kg) 
-38.9±8.1 -78.8±8.2 <0.001 
Glycerol concentration at Baseline 
(micromol/L) 
81.6±24.2 75.1±26.9 0.392 
Glycerol concentration AUC0-180 
(micromol/L*min) 
15279±1748 14684±1388 0.430 
Glycerol concentration incremental 
AUC0-180 (micromol/L*min) 
3412±574 3524±549 0.801 
Glycerol Ra at Baseline 
(micromol/min/kg) 
2.71±0.46 2.17±0.28 0.134 
Glycerol Ra AUC0-180 (micromol/kg) 585±77 543±56 0.048 
Glycerol Ra incremental AUC0-180 
(micromol/kg) 
66.3±15.0 98.2±22.5 0.129 
BOHB concentration at baseline 
(mmol/L) 
0.39±0.11 0.16±0.05 0.044 
AUC0-180 BOHB concentration 
(mmol/L*min) 
149±26 117±18 0.035 
Incremental AUC0-180 BOHB 
concentration (mmol/L*min) 
79.6±13.3 88.1±15.4 0.588 
NEFA concentration at baseline 
(mmol/L) 
0.61±0.09 0.47±0.07 0.054 
 
Significance between BMI groups, P value * <0.05; †<0.01, **<0.001 
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Table 2. Baseline, AUC and incremental AUC from 0-180 min for glucose, glycerol 
and BOHB metabolism at the end of 7 days treatment with dapagliflozin or placebo 
in BMI subgroups. 
 Dapagliflozin 
BMI <27 
kg/m2 
Dapagliflozin 
BMI >27 
kg/m2 
Placebo BMI 
<27 kg/m2 
placebo 
BMI >27 
kg/m2 
BMI 
<27 
Dapa 
vs 
Placeb
o P 
Value 
BMI >
27 
Dapa 
vs 
Placeb
o P 
Value 
Age (y) 34.4±1.9 49.4±1.5* 34.6±1.9 49.4±1.5*   
BMI (kg/m2) 22.5±0.4 31.4±0.3** 22.9±0.4 31.4±0.4**   
Glucose 
concentration at 
baseline (mmol/L) 
5.4±0.1 5.5±0.1 5.8±0.1 5.6±0.1 0.177 0.694 
AUC0-180 glucose 
concentration 
(mmol/L*min) 
1420±43 1498±30 1827±53 1651±44 0.019 0.360 
Incremental AUC0-
180 glucose 
concentration 
(mmol/L*min) 
415±46 535±34 778±45 648±51 0.024 0.414 
Glucose Ra at 
Baseline 
(micromol/min/kg) 
14.5±0.3 11.0±0.3† 12.5±0.4 10.5±0.2 0.001 0.528 
Glucose Ra AUC0-
180 (micromol/kg) 
3524±161 3076±125 3250±116 2579±98 0.428 0.235 
Glucose Ra 
incremental AUC0-
180 (micromol/kg) 
790±106 1002±94 978±53 529±106 0.631 0.175 
Glucose Rd at 
Baseline 
(micromol/min/kg) 
14.6±0.3 11.05±0.3† 12.7±0.4 10.6±0.2 0.001 0.521 
Glucose Rd AUC0-
180 (micromol/kg) 
3000±126 2347±76 2230±76 1692±27 0.009 0.175 
Glucose Rd 
incremental AUC0-
180 (micromol/kg) 
635±87 546±56 279±42 50±16 0.378 0.037 
Glucose MCR at 
Baseline 
(ml/min/kg) 
2.7±0.1 2.0±0.1† 2.22±0.1 1.9±0.0 0.002 0.285 
Glucose MCR 
AUC0-180 (ml/kg) 
389±12 286±7† 228±4 195±3 <0.00
1 
0.007 
Glucose MCR 
incremental AUC0-
180 (ml/kg) 
-35.9±4.9 -42±4.0 -99.3±10.8 -92±7.0 0.039 0.002 
Glycerol 
concentration at 
Baseline 
(micromol/L) 
112.9±14.2 37.9±4.2 104.5±16.5 33.9±2.9 0.426 0.752 
Glycerol 
concentration 
AUC0-180 
(micromol/L*min) 
17428±1007 12270±525 16477±771 12174±49
1 
0.396 0.876 
23 
 
Glycerol 
concentration 
incremental AUC0-
180 (micromol/L*min) 
3624±300 3115±403 3185±239 3999±460 0.455 0.212 
Glycerol Ra at 
Baseline 
(micromole/min/kg) 
3.41±0.23 1.73±0.20* 2.60±0.12 1.57±0.17 0.118 0.648 
Glycerol Ra AUC0-
180 (micromol/kg) 
6.94±41 433±31* 637±27 411±24 0.012 0.866 
Glycerol Ra 
incremental AUC0-
180 (micromol/kg) 
59.7±5.8 75.8±13.8 107.5±12.7 85.1±13.5 0.119 0.661 
BOHB 
concentration at 
baseline (mmol/L) 
0.6±0.05 0.10±0.03† 0.23±0.06 0.06±0.01 0.019 0.703 
AUC0-180 BOHB 
concentration 
(mmol/L*min) 
196±11 84±12† 156±6 62±7* 0.071 0.273 
Incremental AUC0-
180 BOHB 
concentration 
(mmol/L*min) 
89±7 66±8 114±8 52±6* 0.219 0.521 
Insulin 
concentration 
(pmol/L) at Baseline 
154±22 298±25 159±11 341±39* 0.316 0.924 
 
Significance between BMI groups, P value * <0.05; †<0.01, **<0.001 
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Figure 1: Paired plasma glucose concentration (A), Glucose Ra (B) and Glucose Rd 
(C) and Glycerol Ra (D). All subjects completed 180 minutes of each metabolic study 
(n=12). By 480 min n=5.  Dapagliflozin closed symbols. Placebo open symbols. 
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Figure 2: Paired concentration of capillary ketones (A) Beta hydroxybutyrate (B) and 
NEFA (C) in plasma, and venous blood bicarbonate (D). All subjects completed 180 
minutes of each metabolic study (n=12). By 480 min n=5.  Dapagliflozin closed 
symbols and placebo open symbols.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
